Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...

Department of Chemistry, King’s College London, Britannia House, 7 Trinity Street, London SE1 1DB, U.K.